CytoSorbents Corp. (NASDAQ:CTSO) – Investment analysts at B. Riley boosted their FY2016 earnings estimates for CytoSorbents Corp. in a report issued on Tuesday. B. Riley analyst A. D’silva now expects that the brokerage will post earnings of ($0.40) per share for the year, up from their previous forecast of ($0.41). B. Riley currently has a “Buy” rating and a $11.25 price target on the stock. B. Riley also issued estimates for CytoSorbents Corp.’s FY2018 earnings at ($0.30) EPS.

CTSO has been the subject of a number of other research reports. Maxim Group set a $8.00 target price on CytoSorbents Corp. and gave the stock a “buy” rating in a report on Thursday, September 8th. HC Wainwright reiterated a “buy” rating on shares of CytoSorbents Corp. in a report on Tuesday. Brean Capital initiated coverage on CytoSorbents Corp. in a report on Tuesday, October 4th. They set a “buy” rating and a $24.00 target price for the company. Finally, Aegis initiated coverage on CytoSorbents Corp. in a report on Wednesday, October 26th. They set a “buy” rating and a $20.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $15.05.

CytoSorbents Corp. (NASDAQ:CTSO) opened at 5.55 on Thursday. CytoSorbents Corp. has a 52-week low of $3.11 and a 52-week high of $7.54. The company’s 50 day moving average price is $5.82 and its 200 day moving average price is $5.03. The firm’s market cap is $141.18 million.

Several institutional investors have recently made changes to their positions in CTSO. Citadel Advisors LLC bought a new position in shares of CytoSorbents Corp. during the third quarter valued at $106,000. BlackRock Institutional Trust Company N.A. boosted its position in shares of CytoSorbents Corp. by 13.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 29,955 shares of the company’s stock valued at $192,000 after buying an additional 3,495 shares during the last quarter. Finally, Advisor Group Inc. boosted its position in shares of CytoSorbents Corp. by 1.1% in the third quarter. Advisor Group Inc. now owns 305,145 shares of the company’s stock valued at $1,953,000 after buying an additional 3,300 shares during the last quarter. Institutional investors own 6.81% of the company’s stock.

About CytoSorbents Corp.

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

5 Day Chart for NASDAQ:CTSO

Receive News & Stock Ratings for CytoSorbents Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoSorbents Corp. and related stocks with our FREE daily email newsletter.